Twist Bioscience Corporation
NASDAQTwist Bioscience enters the week with the Street aggressively revising upward, even as a 40% one-month rally has already run well past most of those fresh targets. The analyst angle is the defining tension right now. Barclays raised its price target to $95 from $65 on June 24 — a 46% lift in a single move — while maintaining its Overweight rating. That followed TD Cowen lifting to…
Snapshot as of 24 Jun 2026
Twist Bioscience enters the week with the Street aggressively revising upward, even as a 40% one-month rally has already run well past most of those fresh targets. The analyst angle is the defining tension right now.…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for TWST — free to start on ORTEX.
Sign up for free →Open TWST on ORTEX